论文部分内容阅读
有报道称磷酸二酯酶5(PDE_5)抑制具有潜在危害,而且可以增加冠状动脉疾病患者心脏事件的风险。Patrizi R等人进行了一项评价PDE-5抑制剂是否会对接受β受体阻滞剂治疗的患者心肌缺血产生影响。研究中,14名患者无治疗下接受基线运动试验,然后开始氨酰心安治疗(100mg,1d/次)。入组一周后,接受第二次运动试验,隔两天后按不同的两种情况以随机方式
It has been reported that phosphodiesterase 5 (PDE_5) inhibition is potentially harmful and may increase the risk of cardiac events in patients with coronary artery disease. Patrizi R et al conducted a review of whether PDE-5 inhibitors affect myocardial ischemia in patients receiving beta-blocker therapy. In the study, 14 patients underwent baseline exercise without treatment and then began the Atypical Etanercept (100 mg, 1 d / dose). One week after enrolling, they received a second exercise test, two days later in two different situations in a randomized manner